MX2012011636A - Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en eltratamiento de enfermedades asociadas a una proliferacion celulara no deseada. - Google Patents
Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en eltratamiento de enfermedades asociadas a una proliferacion celulara no deseada.Info
- Publication number
- MX2012011636A MX2012011636A MX2012011636A MX2012011636A MX2012011636A MX 2012011636 A MX2012011636 A MX 2012011636A MX 2012011636 A MX2012011636 A MX 2012011636A MX 2012011636 A MX2012011636 A MX 2012011636A MX 2012011636 A MX2012011636 A MX 2012011636A
- Authority
- MX
- Mexico
- Prior art keywords
- lif
- antibodies
- diseases associated
- cell proliferation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5415—Leukaemia inhibitory factor [LIF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Radiology & Medical Imaging (AREA)
Abstract
La invención se refiere a anticuerpos dirigidos contra el factor de inhibición de la leucemia humana (LIF) y a una línea de células de hibridoma productor de dichos anticuerpos. La invención también se refiere a un procedimiento para bloquear/inhibir la proliferación de las células madre y a un procedimiento in vitro para el diagnóstico de enfermedades asociadas a la proliferación celular no deseada o, para determinar la predisposición de un sujeto para sufrir dicha enfermedad asociada a proliferación celular no deseada o para el pronóstico de la esperanza de vida de un sujeto que sufre dicha enfermedad. El potencial terapéutico de dichos anticuerpos se basa en observar que la inhibición de LIF se puede usar en composiciones terapéuticas para el tratamiento de enfermedades asociadas a proliferación no deseada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10380049A EP2371860A1 (en) | 2010-04-05 | 2010-04-05 | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
PCT/EP2011/055253 WO2011124566A1 (en) | 2010-04-05 | 2011-04-05 | Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012011636A true MX2012011636A (es) | 2013-04-03 |
Family
ID=42338260
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008974A MX365054B (es) | 2010-04-05 | 2011-04-05 | Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en el tratamiento de enfermedades asociadas a una proliferacion celular no deseada. |
MX2012011636A MX2012011636A (es) | 2010-04-05 | 2011-04-05 | Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en eltratamiento de enfermedades asociadas a una proliferacion celulara no deseada. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008974A MX365054B (es) | 2010-04-05 | 2011-04-05 | Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en el tratamiento de enfermedades asociadas a una proliferacion celular no deseada. |
Country Status (25)
Country | Link |
---|---|
US (3) | US8926956B2 (es) |
EP (3) | EP2371860A1 (es) |
JP (2) | JP6289906B2 (es) |
KR (5) | KR20130121679A (es) |
CN (2) | CN103797031A (es) |
AU (1) | AU2011237922B2 (es) |
BR (1) | BR112012025517B1 (es) |
CA (1) | CA2797257A1 (es) |
CY (1) | CY1119451T1 (es) |
DK (1) | DK2556091T3 (es) |
EA (2) | EA202092276A3 (es) |
ES (1) | ES2608699T3 (es) |
HK (3) | HK1180702A1 (es) |
HR (1) | HRP20161736T1 (es) |
HU (1) | HUE030578T2 (es) |
IL (3) | IL222270A (es) |
LT (1) | LT2556091T (es) |
MX (2) | MX365054B (es) |
PL (1) | PL2556091T3 (es) |
PT (1) | PT2556091T (es) |
RS (1) | RS55539B1 (es) |
SG (1) | SG184429A1 (es) |
SI (1) | SI2556091T1 (es) |
SM (1) | SMT201600468T1 (es) |
WO (1) | WO2011124566A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1904093B1 (en) * | 2005-07-19 | 2018-06-13 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by bmp-4 |
EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
US20160237158A1 (en) * | 2013-09-23 | 2016-08-18 | Institut National De La Santé Et Da La Recherche Médicale (Inserm) | Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis |
TWI486172B (zh) * | 2013-11-08 | 2015-06-01 | Univ Chang Gung | 鼻咽癌治療的醫藥 |
US20170247446A1 (en) * | 2014-09-10 | 2017-08-31 | The Regents Of The University Of California | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES |
AU2016235298B2 (en) | 2015-03-23 | 2021-03-11 | Evestra, Inc. | Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents |
EP3173483A1 (en) * | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
JP7100056B2 (ja) | 2016-12-19 | 2022-07-12 | メディミューン リミテッド | Lifに対する抗体及びその使用 |
US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
KR20210021287A (ko) | 2018-04-12 | 2021-02-25 | 메디뮨 리미티드 | 암을 치료하는 데 사용하기 위한 lif 억제제와 pd-1 축 억제제의 조합 |
MA52021A (fr) * | 2018-05-14 | 2021-03-24 | Fundacio Privada Inst Catalana De Recerca I Estudis Avancats | Anticorps anti-lif et leurs formes galéniques |
SG11202012619WA (en) * | 2018-06-18 | 2021-01-28 | Medimmune Ltd | Methods for improving response to anti-lif antibody treatment in individuals with cancer |
EA202092964A1 (ru) * | 2018-06-18 | 2021-03-30 | Медиммун Лимитед | Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака |
MX2022003762A (es) * | 2019-09-29 | 2022-06-24 | Jacobio Pharmaceuticals Co Ltd | Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma. |
CN111020030A (zh) * | 2019-12-03 | 2020-04-17 | 中山大学 | 一种骨肉瘤干细胞标志物及其应用、试剂盒 |
CN111378036B (zh) * | 2020-01-09 | 2021-08-10 | 北京浩古元方生物医药科技有限公司 | 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用 |
CN112294812B (zh) * | 2020-11-18 | 2022-08-16 | 新乡医学院 | 一种小分子抑制剂在制备抗肿瘤药物方面的应用 |
CN114672460B (zh) * | 2021-12-21 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向cd44的异质型cic细胞模型的制备方法及应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB9004890D0 (en) | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
JPH05304986A (ja) | 1992-04-28 | 1993-11-19 | Tosoh Corp | gp130蛋白質に対するモノクロ−ナル抗体 |
AU4231393A (en) | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
WO1993023665A1 (en) | 1992-05-15 | 1993-11-25 | Re/Map Incorporated | Electromagnetic shielding for a liquid conditioning device |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
ATE233570T1 (de) * | 1995-04-24 | 2003-03-15 | Genentech Inc | Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten |
US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
EP1497445A2 (en) | 2002-04-01 | 2005-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
AU2003262717A1 (en) * | 2002-08-15 | 2004-03-03 | Genzyme Corporation | Brain endothelial cell expression patterns |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2005030803A1 (en) | 2003-09-29 | 2005-04-07 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
EP1752536A4 (en) | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
EP1612558A1 (en) | 2004-06-30 | 2006-01-04 | Academisch Ziekenhuis Leiden | Method for detecting gluten |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
WO2008043052A2 (en) | 2006-10-04 | 2008-04-10 | The Scripps Research Institute | Human antibodies neutralizing human metapneumovirus |
CN101440128A (zh) * | 2007-11-21 | 2009-05-27 | 中国人民解放军第二军医大学 | 人脑胶质瘤中差异表达的蛋白及其用途 |
WO2010054499A1 (en) * | 2008-11-11 | 2010-05-20 | Telefonaktiebolaget L M Ericsson (Publ) | A dpd system with multiple transmitter paths |
ES2363358B1 (es) | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
WO2011057144A2 (en) | 2009-11-06 | 2011-05-12 | La Jolla Institute For Allergy And Immunology | Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses |
CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
TWI486172B (zh) | 2013-11-08 | 2015-06-01 | Univ Chang Gung | 鼻咽癌治療的醫藥 |
-
2010
- 2010-04-05 EP EP10380049A patent/EP2371860A1/en not_active Withdrawn
-
2011
- 2011-04-05 RS RS20161123A patent/RS55539B1/sr unknown
- 2011-04-05 JP JP2013503084A patent/JP6289906B2/ja active Active
- 2011-04-05 WO PCT/EP2011/055253 patent/WO2011124566A1/en active Application Filing
- 2011-04-05 CA CA2797257A patent/CA2797257A1/en not_active Abandoned
- 2011-04-05 SI SI201131028A patent/SI2556091T1/sl unknown
- 2011-04-05 MX MX2015008974A patent/MX365054B/es unknown
- 2011-04-05 EP EP16154907.6A patent/EP3045473A1/en not_active Withdrawn
- 2011-04-05 KR KR1020127028860A patent/KR20130121679A/ko not_active Application Discontinuation
- 2011-04-05 KR KR1020187018882A patent/KR20180078352A/ko active Application Filing
- 2011-04-05 DK DK11715676.0T patent/DK2556091T3/en active
- 2011-04-05 LT LTEP11715676.0T patent/LT2556091T/lt unknown
- 2011-04-05 EA EA202092276A patent/EA202092276A3/ru unknown
- 2011-04-05 HU HUE11715676A patent/HUE030578T2/en unknown
- 2011-04-05 US US13/261,464 patent/US8926956B2/en active Active
- 2011-04-05 MX MX2012011636A patent/MX2012011636A/es active IP Right Grant
- 2011-04-05 KR KR1020207028482A patent/KR102294207B1/ko active IP Right Grant
- 2011-04-05 ES ES11715676.0T patent/ES2608699T3/es active Active
- 2011-04-05 KR KR1020177031786A patent/KR20170125137A/ko not_active Application Discontinuation
- 2011-04-05 EA EA201201373A patent/EA036698B9/ru not_active IP Right Cessation
- 2011-04-05 BR BR112012025517-7A patent/BR112012025517B1/pt not_active IP Right Cessation
- 2011-04-05 PT PT117156760T patent/PT2556091T/pt unknown
- 2011-04-05 AU AU2011237922A patent/AU2011237922B2/en not_active Ceased
- 2011-04-05 PL PL11715676T patent/PL2556091T3/pl unknown
- 2011-04-05 EP EP11715676.0A patent/EP2556091B1/en active Active
- 2011-04-05 KR KR1020197015171A patent/KR20190061098A/ko not_active Application Discontinuation
- 2011-04-05 SG SG2012073557A patent/SG184429A1/en unknown
- 2011-04-05 CN CN201180027552.6A patent/CN103797031A/zh active Pending
- 2011-04-05 CN CN201810679717.1A patent/CN109320609A/zh active Pending
-
2012
- 2012-10-09 IL IL222270A patent/IL222270A/en active IP Right Grant
-
2013
- 2013-07-10 HK HK13108092.5A patent/HK1180702A1/zh not_active IP Right Cessation
- 2013-07-10 HK HK16111721.5A patent/HK1223384A1/zh unknown
-
2014
- 2014-11-04 HK HK14111011.6A patent/HK1208469A1/xx unknown
-
2015
- 2015-01-05 US US14/589,033 patent/US20150139989A1/en not_active Abandoned
- 2015-10-07 IL IL241952A patent/IL241952A/en active IP Right Grant
-
2016
- 2016-07-01 JP JP2016131179A patent/JP6483059B2/ja active Active
- 2016-12-16 HR HRP20161736TT patent/HRP20161736T1/hr unknown
- 2016-12-22 SM SM201600468T patent/SMT201600468T1/it unknown
- 2016-12-22 CY CY20161101328T patent/CY1119451T1/el unknown
-
2017
- 2017-09-25 IL IL254664A patent/IL254664B/en unknown
-
2018
- 2018-05-14 US US15/978,362 patent/US10968273B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012011636A (es) | Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en eltratamiento de enfermedades asociadas a una proliferacion celulara no deseada. | |
MX336903B (es) | Agentes terapeuticos para el tratamiento de enfermedades asociadas con una proliferacion celular indeseada. | |
WO2007133822A8 (en) | Gitr antibodies for the treatment of cancer | |
MX2020009704A (es) | Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal. | |
WO2012081898A3 (ko) | 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 | |
MX2012011543A (es) | Tratamiento de sarcoidosis empleando celulas madre placentarias. | |
MX2013000916A (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales. | |
MX2009002936A (es) | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. | |
MX2019001414A (es) | Angiogenesis utilizando celulas madre placentarias. | |
TN2012000555A1 (en) | Antibodies to human gdf8 | |
MX2011012913A (es) | Métodos para evaluar el riesgo de cáncer de mama. | |
MX2011012680A (es) | Ligandos peptoides para aislamiento y tratamiento de celulas-t autoinmune. | |
NZ609594A (en) | Eph receptor expression in tumor stem cells | |
MX2014000066A (es) | Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana. | |
NZ602515A (en) | Proteins that bind pi16 and uses thereof | |
NZ631639A (en) | Methods and compositions for treating and diagnosing acute myocardial infarction | |
EA201490201A1 (ru) | Выявление экспрессии гена prame при раковом заболевании | |
WO2010126279A3 (ko) | 사이토케라틴17-특이적인 인간항체 | |
WO2013070807A8 (en) | Niche targeting of quiescent cancer stem cells | |
MX2022003159A (es) | Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos. | |
MX2013012648A (es) | Metodo para determinar hipoxia clinicamente relevante en cancer. | |
MX2008016493A (es) | Metodo para la deteccion de diagnostico de cancer que implica cebadores y sondas para la deteccion especifica del marcador mage-3. | |
WO2009072831A3 (en) | Novel use of flj25416 gene | |
MX352296B (es) | Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades. | |
EP2540742A1 (en) | MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |